LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma

Summary

The purpose of this trial is to evaluate the disease control rate of nintedanib in subjects with metastatic appendiceal cancer for whom initial fluoropyrimidine-based chemotherapy has failed. Based on previous studies, the anticancer activity of nintedanib in lung and ovarian cancer trials, along with the similarities between appendiceal and colorectal cancer and potentially ovarian cancer, warrant additional investigation for the optimal treatment of metastatic appendiceal carcinomas.

Timeline

Start

2017-11-10

Primary completion

2019-09-03

Completion

2019-10-27

Drugs

Indications